Human leukocyte antigen class II DRB1*1302 allele protects against cervical cancer: At which step of multistage carcinogenesis?
Human leukocyte antigen class II DRB1*1302 allele protects against cervical cancer: At which step of multistage carcinogenesis?
复制标题
DOI：
10.1111/cas.12760
复制
发表时间：
2015-10
期刊：
影响因子：
5.7
通讯作者：
Japan HPV and Cervical Cancer (JHACC) Study Group
中科院分区：
文献类型：
--
作者：
Matsumoto K;Maeda H;Oki A;Takatsuka N;Yasugi T;Furuta R;Hirata R;Mitsuhashi A;Kawana K;Fujii T;Iwata T;Hirai Y;Yokoyama M;Yaegashi N;Watanabe Y;Nagai Y;Yoshikawa H;Japan HPV and Cervical Cancer (JHACC) Study Group
我们研究了人类白细胞抗原（HLA）II类等位基因在多阶段宫颈癌发生中的作用。HLA与宫颈癌相关性的横断面分析包括1253名日本女性：正常细胞学（NL，n = 341），宫颈上皮内瘤变1级（CIN 1，n = 505），CIN 2或3级（CIN 2/3，n = 96），或浸润性宫颈癌（ICC，n = 311）。采用Fisher精确检验或χ2检验比较HLA Ⅱ类等位基因频率。Bonferroni调整校正了多重比较。在研究对象中，454名具有低度鳞状上皮内病变细胞学的妇女每3-4个月通过细胞学和阴道镜进行前瞻性监测，以分析与HLA II类等位基因相关的未来10年内CIN 3的累积风险。HLA Ⅱ类DRB 1 *1302等位基因频率在NL组（11.7%）和CIN 1组（11.9%）中相似，但在CIN 2/3组和ICC组中显著降低至5.2%和5.8%（P = 0.0003）。多次检测的纠正并未改变这一结果。在低级别鳞状上皮内病变细胞学检查的女性中，DRB 1 *1302阳性女性10年内诊断为CIN 3的累积风险显著降低（3.2% vs. 23.7%，P = 0.03）。总之，这项研究中的两种不同类型的分析显示了DRB 1 *1302等位基因对从CIN 1进展到CIN 2/3的保护作用。
We investigated the role of human leukocyte antigen (HLA) class II alleles in multistage cervical carcinogenesis. Cross-sectional analysis for HLA association with cervical cancer included 1253 Japanese women: normal cytology (NL, n = 341), cervical intraepithelial neoplasia grade 1 (CIN1, n = 505), CIN grade 2 or 3 (CIN2/3, n = 96), or invasive cervical cancer (ICC, n = 311). The HLA class II allele frequencies were compared by Fisher’s exact test or the χ2-test. The Bonferroni adjustment corrected for multiple comparisons. Among the study subjects, 454 women with low-grade squamous intraepithelial lesion cytology were prospectively monitored by cytology and colposcopy every 3–4 months to analyze cumulative risk of CIN3 within the next 10 years in relation to HLA class II alleles. HLA class II DRB1*1302 allele frequency was similar between women with NL (11.7%) and CIN1 (11.9%), but significantly decreased to 5.2% for CIN2/3 and 5.8% for ICC (P = 0.0003). Correction for multiple testing did not change this finding. In women with low-grade squamous intraepithelial lesion cytology, the cumulative risk of CIN3 diagnosed within 10 years was significantly reduced among DRB1*1302-positive women (3.2% vs. 23.7%, P = 0.03). In conclusion, the two different types of analysis in this single study showed the protective effect of the DRB1*1302 allele against progression from CIN1 to CIN2/3.